# Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

> **NCT01632592** · NA · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Abdominal Obesity

## Interventions

- **DRUG:** Tesamorelin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01632592
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-01
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No funding available
- **Last updated:** 2014-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632592, "Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01632592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*